Goldman resumed coverage on Reata Pharmaceuticals with a new price target
$RETA
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman resumed coverage of Reata Pharmaceuticals with a rating of Buy and set a new price target of $91.00
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/6/2023 | $140.00 | Outperform | TD Cowen |
6/12/2023 | $80.00 → $115.00 | Market Perform → Outperform | SVB Securities |
10/19/2022 | $75.00 | Buy | Guggenheim |
3/24/2022 | $91.00 | Buy | Goldman |
3/1/2022 | $39.00 → $34.00 | Neutral | Goldman Sachs |
12/9/2021 | $39.00 | Buy → Neutral | Goldman Sachs |
12/9/2021 | $110.00 → $37.00 | Outperform → Neutral | Robert W. Baird |
12/9/2021 | $112.00 → $68.00 | Overweight | Cantor Fitzgerald |